Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Sep;2(5):626–630. doi: 10.1128/cdli.2.5.626-630.1995

Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections.

I Tsuboi 1, K Sagawa 1, S Shichijo 1, M M Yokoyama 1, D W Ou 1, M D Wiederhold 1
PMCID: PMC170210  PMID: 8548545

Abstract

In serum, the enzyme adenosine deaminase (ADA) is known to be divided into two isoenzymes, ADA1 and ADA2, which have different molecular weights and kinetic properties. The present study investigated ADA isoenzyme levels in the sera of patients infected with retroviruses associated with adult T-cell leukemia (ATL), human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM), and AIDS, ADA isoenzyme activities were found to be significantly (P < 0.001) higher in the sera of patients with ATL, HAM, and AIDS than in the sera of healthy controls. In the case of the ADA subtypes in the sera of patients with ATL, ADA1 activity was significantly (P < 0.001) elevated in patients with the acute and lymphoma types of ATL compared with that in patients with the chronic and smoldering types of ATL. ADA2 activity was significantly elevated in the sera of patients with the acute, lymphoma, and chronic types of ATL (P < 0.001) compared with that in patients with smoldering ATL and HTLV-1 carriers. In the case of patients with human immunodeficiency virus type 1 (HIV-1) infection, ADA1 and ADA2 activities in the sera of patients with AIDS and HIV-1 antibody-positive individuals were significantly (P < 0.001) higher than those in the sera of HIV-1 antibody-negative individuals. A significant elevation in ADA2 activity was also seen in the sera of AIDS patients (P < 0.01) compared with that in the sera of HIV-1 antibody-positive individuals. These results suggest that the magnitude of elevation of ADA isoenzyme levels in serum correlates well with the clinical conditions of the patients with these diseases. Measurement of the activities of ADA isoenzymes may therefore provide an additional parameter for distinguishing the subtypes of ATL and may prove to be useful as prognostic and therapeutic monitors in diseases associated with HTLV-1 and HIV-1 infections.

Full Text

The Full Text of this article is available as a PDF (182.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bastian G., Bessodes M., Panzica R. P., Abushanab E., Chen S. F., Stoeckler J. D., Parks R. E., Jr Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines. J Med Chem. 1981 Dec;24(12):1383–1385. doi: 10.1021/jm00144a002. [DOI] [PubMed] [Google Scholar]
  2. Blazquez M. V., Madueño J. A., Gonzalez R., Jurado R., Bachovchin W. W., Peña J., Muñoz E. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol. 1992 Nov 1;149(9):3073–3077. [PubMed] [Google Scholar]
  3. Carson D. A., Kaye J., Wasson D. B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol. 1981 Jan;126(1):348–352. [PubMed] [Google Scholar]
  4. Ellis G., Spooner R. J., Goldberg D. M. Automated kinetic assays for routine determination of adenosine deaminase and guanase activities of human serum. Clin Chim Acta. 1973 Aug 17;47(1):75–87. doi: 10.1016/0009-8981(73)90062-4. [DOI] [PubMed] [Google Scholar]
  5. Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. doi: 10.1016/s0140-6736(72)92345-8. [DOI] [PubMed] [Google Scholar]
  6. Hattori T., Uchiyama T., Toibana T., Takatsuki K., Uchino H. Surface phenotype of Japanese adult T-cell leukemia cells characterized by monoclonal antibodies. Blood. 1981 Sep;58(3):645–647. [PubMed] [Google Scholar]
  7. Hegen M., Niedobitek G., Klein C. E., Stein H., Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol. 1990 Apr 15;144(8):2908–2914. [PubMed] [Google Scholar]
  8. Kameoka J., Tanaka T., Nojima Y., Schlossman S. F., Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993 Jul 23;261(5120):466–469. doi: 10.1126/science.8101391. [DOI] [PubMed] [Google Scholar]
  9. Lane H. C., Depper J. M., Greene W. C., Whalen G., Waldmann T. A., Fauci A. S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 1985 Jul 11;313(2):79–84. doi: 10.1056/NEJM198507113130204. [DOI] [PubMed] [Google Scholar]
  10. Ma D. D., Sylwestrowicz T. A., Granger S., Massaia M., Franks R., Janossy G., Hoffbrand A. V. Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes. J Immunol. 1982 Oct;129(4):1430–1435. [PubMed] [Google Scholar]
  11. Muraoka T., Katsuramaki T., Shiraishi H., Yokoyama M. M. Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum. Anal Biochem. 1990 Jun;187(2):268–272. doi: 10.1016/0003-2697(90)90455-i. [DOI] [PubMed] [Google Scholar]
  12. Oda T., Kagimoto T., Aso N., Yamaguchi K., Tomino S., Takatsuki K. Adenosine deaminase in plasma of patients with adult T-cell leukemia (ATL): correlation between enzyme activity and the ATL subtypes. Hematol Oncol. 1985 Jul-Sep;3(3):173–177. doi: 10.1002/hon.2900030305. [DOI] [PubMed] [Google Scholar]
  13. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986 May 3;1(8488):1031–1032. doi: 10.1016/s0140-6736(86)91298-5. [DOI] [PubMed] [Google Scholar]
  14. Plana M., Viñas O., De la Calle-Martin O., Lozano F., Inglés-Esteve J., Romero M., Alberola-Ila J., Yagüe J., Vilella R., Vives J. Induction of interleukin 2 (IL 2) and interferon-gamma and enhancement of IL 2 receptor expression by a CD26 monoclonal antibody. Eur J Immunol. 1991 Apr;21(4):1085–1088. doi: 10.1002/eji.1830210436. [DOI] [PubMed] [Google Scholar]
  15. Ratech H., Hirschhorn R. Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient-severe combined immunodeficiency. Clin Chim Acta. 1981 Sep;115(3):341–347. doi: 10.1016/0009-8981(81)90247-3. [DOI] [PubMed] [Google Scholar]
  16. Ratech H., Martiniuk F., Borer W. Z., Rappaport H. Differential expression of adenosine deaminase isozymes in acute leukemia. Blood. 1988 Nov;72(5):1627–1632. [PubMed] [Google Scholar]
  17. Ratech H., Thorbecke G. J., Meredith G., Hirschhorn R. Comparison and possible homology of isozymes of adenosine deaminase in Aves and humans. Enzyme. 1981;26(2):74–84. doi: 10.1159/000459153. [DOI] [PubMed] [Google Scholar]
  18. Román G. C., Osame M. Identity of HTLV-I-associated tropical spastic paraparesis and HTLV-I-associated myelopathy. Lancet. 1988 Mar 19;1(8586):651–651. doi: 10.1016/s0140-6736(88)91452-3. [DOI] [PubMed] [Google Scholar]
  19. Schrader W. P., Pollara B., Meuwissen H. J. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):446–450. doi: 10.1073/pnas.75.1.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van der Weyden M. B., Kelley W. N. Human adenosine deaminase. Distribution and properties. J Biol Chem. 1976 Sep 25;251(18):5448–5456. [PubMed] [Google Scholar]
  21. Wortmann R. L., Mitchell B. S., Edwards N. L., Fox I. H. Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A. 1979 May;76(5):2434–2437. doi: 10.1073/pnas.76.5.2434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yasuda K., Sei Y., Yokoyama M. M., Tanaka K., Hara A. Healthy HTLV-I carriers in Japan: the haematological and immunological characteristics. Br J Haematol. 1986 Sep;64(1):195–203. doi: 10.1111/j.1365-2141.1986.tb07587.x. [DOI] [PubMed] [Google Scholar]
  23. Yokoyama M. M., Tsuboi I. Adenosine deaminase isoenzymes and HIV/HTLV-1 infections. J Natl Cancer Inst. 1988 Jul 6;80(9):698–698. doi: 10.1093/jnci/80.9.698. [DOI] [PubMed] [Google Scholar]
  24. van Laarhoven J. P., Spierenburg G. T., Collet H., Delespesse G., De Bruyn C. H. Purine interconversion pathways in T, B, T gamma and T-T gamma cells from human peripheral blood. Adv Exp Med Biol. 1984;165(Pt B):111–118. doi: 10.1007/978-1-4757-0390-0_23. [DOI] [PubMed] [Google Scholar]
  25. van Laarhoven J. P., de Bruyn C. H. Purine metabolism in relation to leukemia and lymphoid cell differentiation. Leuk Res. 1983;7(4):451–480. doi: 10.1016/0145-2126(83)90042-5. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES